OCRA has awarded 450+ grants and invested $140 million in ovarian cancer and related gynecologic cancer research initiatives, becoming the largest global charity devoted to ovarian and related gynecologic cancer research in the world.
OCRA has awarded 450+ grants and invested $140 million in ovarian cancer and related gynecologic cancer research initiatives, becoming the largest global charity devoted to ovarian and related gynecologic cancer research in the world.
Our commitment to cutting-edge research has resulted in scientific breakthroughs that are igniting hope worldwide and galvanizing top researchers as never before.
OCRA is proud to support groundbreaking ovarian cancer and related gynecologic cancer research. With an annual grantmaking budget of over $7 million, we fund scientists at all stages of their careers. OCRA-funded scientists are working in areas ranging from AI and basic science to clinical and translational research. They are also exploring disease at the cellular and molecular level.
Ovarian Cancer Research Alliance is proud to present the 16th Biennial Ovarian Cancer Research Symposium. The event will take place in Philadelphia on October 16-18, 2026.
Our researchers come from across the country and around the globe. While their areas of research may differ, they are united in their passion to find a cure and their desire to collaborate and innovate to improve the lives of patients.
OCRA’s new research partnership, The Edmée Firth Fund for Research in Ovarian Cancer (EFFROC), is funding research to develop clinical testing methods and education to increase physicians’ awareness of the disease and the importance of early detection. It is also funding research into ways to reduce the toxicity and side effects of second-line treatments and to improve targeted therapies.
On March 25, 2026, the FDA approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA approval of Keytruda (pembrolizumab) with … Continued
OCRA’s Annual Advocacy Day Draws Survivors and Caregivers from Across the Country More than 120 gynecologic cancer survivors, caregivers, researchers and supporters from nearly forty states filled the halls of the U.S. Capitol on Tuesday, March 17—dressed in teal, the color of ovarian cancer awareness—as Ovarian Cancer Research Alliance (OCRA) held its annual Spring Advocacy Day. The … Continued
Recognizing Advances in Ovarian Cancer Research and Immunotherapy Ovarian Cancer Research Alliance (OCRA) announced today the winners of two prizes recognizing exceptional accomplishments in ovarian cancer research. David Huntsman, MD, FRCPC, FCCMG, was awarded the 2025 Rosalind Franklin Prize for Excellence in Ovarian Cancer Research for his findings that have profoundly impacted the treatment of … Continued
Get email updates about research news, action alerts, and ways to join the fight.
